News Briefs: Siemens-Pfizer Dx Pact; Pancreatic Stent; AtriCure Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Siemens teams with Pfizer on companion Dx. XLumena gains pancreatic stent approval. AtriCure acquires Estech. More news.
You may also be interested in...
Boston Scientific Picks Up Pancreatic Stent Maker Xlumena
In the $62.5 million-plus-milestone deal Boston Scientific gets Xlumena's Axios and Hot Axios stent and delivery systems for endoscopic ultrasound-guided transluminal drainage of symptomatic pancreatic pseudocysts. The products fit alongside Boston's Expect endoscopic ultrasound aspiration needles.
Boston Scientific Announces Six ICD/CRT-D Approvals
Boston Scientific announced FDA approval of the Dynagen Mini and Inogen Mini ICDs, which it claims are the thinnest and smallest ICDs available, and the Dynagen X4 and Inogen X4 quadripolar CRT-Ds.
FDA, Congress Look To Nationalize Breast Density Reporting Requirements, Now In 13 States
FDA hopes to finish drafting a proposed rule by early next year requiring mammography screening professionals to notify women and their physicians of dense breast tissue that may warrant further imaging follow-up with MRI and ultrasound. Meanwhile, a bill was recently introduced in Congress on the same topic.